Showing results (181-190 of 288) with videos related to

Sort By:
Pageof 29
Leukemia Research|January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Molecular Cancer Therapeutics|April 17, 2012
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemiaJeremy B Samon, Mireia Castillo-Martin, Michael Hadler, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood|September 27, 2003
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupJacob M Rowe, Donna Neuberg, William Friedenberg, et al.
Leukemia & Lymphoma|December 29, 2004
Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)Janice P Dutcher, Sandra Lee, Robert E Gallagher, et al.
Blood|July 1, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)Peter L Greenberg, Zhuoxin Sun, Kenneth B Miller, et al.
British Journal of Haematology|October 7, 2009
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow, Megan Othus, Larry D Cripe, et al.
Leukemia & Lymphoma|December 29, 2004
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995)Peter A Cassileth, Sandra J Lee, Mark R Litzow, et al.
Nature Reviews. Clinical Oncology|September 6, 2012
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachJan J Cornelissen, Alois Gratwohl, Richard F Schlenk, et al.
Blood|August 3, 2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900Mithat Gönen, Zhuoxin Sun, Maria E Figueroa, et al.
Pageof 29